Spyre Therapeutics, Inc. (SYRE)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20260 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Spyre Therapeutics, Inc.’s names, not what it holds today.
3 published
1 published
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Feb 22, 2024 | 2024/0058429 | Treatment Of Homocystinuria And Hyperhomocysteinemia Using Cystathionine-Gamma-Lyase | Pharmaceuticals | Aeglea BioTherapeutics, Inc. |
| Jun 24, 2021 | 2021/0189371 | Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof | Chemical engineering | Aeglea BioTherapeutics, Inc. |
| Nov 19, 2020 | 2020/0360493 | Compositions and Methods for Treating Cancer with Arginine Depletion and Immuno Oncology Agents | Pharmaceuticals | Aeglea BioTherapeutics, Inc. |
| Jun 28, 2018 | 2018/0177853 | Compositions and Methods for Treating Cancer with Arginine Depletion and Immuno Oncology Agents | Pharmaceuticals | Aeglea BioTherapeutics, Inc. · patent 10,729,752 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.